Tsubota Laboratory Incorporated Logo

Tsubota Laboratory Incorporated

Developing pharmaceuticals and medical devices for ophthalmic and brain diseases.

4890 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
新宿区信濃町35 慶應義塾大学信濃町キャンパス2号館9階CRIK信濃町E7
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Tsubota Laboratory Incorporated is a bio-venture company that originated as a startup from Keio University. The firm is engaged in the research and development of innovative pharmaceuticals and medical devices. Its primary focus is on creating solutions for ophthalmic conditions such as myopia, dry eye, and presbyopia. The company also extends its research into treatments for brain diseases, including depression and dementia, notably exploring the application of technologies like violet light therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-27 04:35
Post-Annual General Meeting Information
臨時報告書
Japanese 23.3 KB
2025-06-26 09:02
Regulatory News Service
確認書
Japanese 9.4 KB
2025-06-26 09:01
Regulatory News Service
内部統制報告書-第13期(2024/04/01-2025/03/31)
Japanese 23.5 KB
2025-06-26 09:01
Annual Report
有価証券報告書-第13期(2024/04/01-2025/03/31)
Japanese 1.6 MB
2024-11-14 08:02
Regulatory News Service
確認書
Japanese 9.0 KB
2024-11-14 08:02
Interim Report
半期報告書-第13期(2024/04/01-2025/03/31)
Japanese 201.7 KB
2024-06-27 04:10
Governance Information
内部統制報告書-第12期(2023/04/01-2024/03/31)
Japanese 22.8 KB
2024-06-27 04:09
Regulatory News Service
確認書
Japanese 8.9 KB
2024-06-27 04:08
Annual Report
有価証券報告書-第12期(2023/04/01-2024/03/31)
Japanese 1.7 MB
2024-02-14 07:11
Report Publication Announcement
確認書
Japanese 9.0 KB
2024-02-14 07:10
Quarterly Report
四半期報告書-第12期第3四半期(2023/10/01-2023/12/31)
Japanese 160.1 KB
2023-11-13 07:06
Report Publication Announcement
確認書
Japanese 9.0 KB
2023-11-13 07:02
Quarterly Report
四半期報告書-第12期第2四半期(2023/07/01-2023/09/30)
Japanese 193.0 KB
2023-08-14 09:17
Report Publication Announcement
確認書
Japanese 9.0 KB
2023-08-14 09:16
Quarterly Report
四半期報告書-第12期第1四半期(2023/04/01-2023/06/30)
Japanese 153.7 KB

Automate Your Workflow. Get a real-time feed of all Tsubota Laboratory Incorporated filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Tsubota Laboratory Incorporated via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Mural Oncology PLC Logo
Clinical-stage company developing cytokine immunotherapies for hard-to-treat solid tumors.
N/A
NANO MRNA Co.,Ltd. Logo
Biotech IP generator developing and licensing mRNA therapeutics using proprietary delivery systems.
Japan 4571
NATURECELL CO.,LTD. Logo
Biotech company developing stem cell therapies, food, beverages, and cosmetics.
South Korea 007390
A marketing support firm using a vast consumer panel for data-driven research and PR campaigns.
Japan 4196
Neovacs Logo
Develops immunotherapy vaccines for autoimmune diseases & invests in BioTech/MedTech companies.
France ALNEV
Mineral explorer of rare earths, niobium, uranium, and copper assets in Australia and Zambia.
Australia N/A
NFL Biosciences Logo
Develops botanical drug candidates to treat smoking and alcohol addictions.
France ALNFL
NGS Group Logo
Nordic staffing & recruitment for healthcare, education, and social services sectors.
Sweden NGS
Nihon M&A Center Holdings Inc. Logo
M&A advisory firm specializing in brokerage and consulting for Japanese SMEs, including cross-border deals.
Japan 2127
Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan 4893

Talk to a Data Expert

Have a question? We'll get back to you promptly.